ArticleOncology2015
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma.
Article in Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.BMC cancer · 2018Pooled it
- Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma.The oncologist · 2022Trial
- Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).Journal for immunotherapy of cancer · 2021Trial
- Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Clinicopathological features, treatment outcomes, and prognostic factors of angiosarcoma: a 21-year experience at one center.Orphanet journal of rare diseases · 2025Article
- Genomic landscape and preclinical models of angiosarcoma.Molecular oncology · 2025Review
- A Malignant Masquerade: Angiosarcoma Presenting as an Impending Rupture of an Abdominal Aortic Aneurysm.Cureus · 2025Article
- High-Throughput Transcriptomics Identifies Chemoresistance-Associated Gene Expression Signatures in Human Angiosarcoma.International journal of molecular sciences · 2024Article
- miR-497 Target Gene Regulatory Network in Angiosarcoma.Molecular cancer research : MCR · 2024Article
- Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review.Journal of clinical medicine · 2024Review
- Current understanding of angiosarcoma: disease biology and evolving treatment.Archives of craniofacial surgery · 2023Article
- Target gene regulatory network of miR-497 in angiosarcoma.bioRxiv : the preprint server for biology · 2023Article
- Clinical Outcomes of Radiation Therapy for Angiosarcoma of the Scalp and Face: A Multi-Institutional Observational Study.Cancers · 2023Article
- Clinicopathological characteristics and survival outcomes in patients with angiosarcoma of breast.Cancer medicine · 2023Article
- Principles of medical and oncological management of giant masses of the mediastinum: a narrative review.Mediastinum (Hong Kong, China) · 2022Review
- Review
- Primary Aortic Angiosarcoma: A Review of Two Cases Highlighting Unique Imaging and Clinical Characteristics.Radiology. Cardiothoracic imaging · 2021Article
- Multiple Firm Livid Nodules on the Proximal Lower Leg: A Quiz.Acta dermato-venereologica · 2021Article
- Current Management of Angiosarcoma: Recent Advances and Lessons From the Past.Current treatment options in oncology · 2021Review
- Primary breast angiosarcoma with disseminated intravascular coagulation is successfully treated with self-subcutaneous unfractionated heparin calcium injection: A case report.Molecular and clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundAngiosarcomas (AS) are rare tumors of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of patients treated for metastatic disease.
methodsWe performed a retrospective analysis of 119 patients treated for metastatic AS. Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed.
resultsMedian age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) patients received ≥ 2 and ≥ 3 lines of therapy, respectively. The most commonly used agents included taxanes and anthracyclines. Median overall survival was 12.1 months. Median times to tumor progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 patients evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. Doxorubicin, liposomal doxorubicin and taxanes resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy.
conclusionDespite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic AS, and outcomes are poor. Doxorubicin, liposomal doxorubicin and taxanes are reasonable and appropriate choices for monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.